SCHEMBL5286296

SCHEMBL5286296

CS(=O)(=O)[CH]Nc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 2/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ CA2 P00918 3/20 0.41
▸ CA1 P00915 2/20 0.41
▸ IL1RN P18510 1/20 0.40
▸ ERAP1 Q9NZ08 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ACP1 P24666 1/20 0.38
▸ BCAT2 O15382 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5281571 0.76 TLR9 (0.50) KEAP1ALDH1A1CA2CA1IL1RN
SCHEMBL11787040 0.72 MAPT (0.56) KEAP1ALDH1A1CA2CA1MAPT
SCHEMBL11331899 0.72 — —
Formanilide SCHEMBL569206 0.70 ALDH1A1 (0.94) ALDH1A1TSHRSMN1; SMN2NPC1NFKB1
SCHEMBL56693 0.69 KEAP1 (1.00) KEAP1ALDH1A1CA2CA1IL1RN
SCHEMBL27360697 0.68 ALDH1A1 (0.50) KEAP1ALDH1A1CA2CA1IL1RN
SCHEMBL23353504 0.67 ALDH1A1 (1.00) ALDH1A1TSHRSMN1; SMN2NPC1NFKB1
SCHEMBL360732 0.67 — —
Formanilide SCHEMBL29177030 0.67 ALDH1A1 (1.00) ALDH1A1TSHRSMN1; SMN2NPC1NFKB1
Formanilide SCHEMBL2463 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 — — WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 — — US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 — — WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KEAP1 4633/4885ALDH1A1 2972/4885CA2 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback